Sildenafil warnings describe clinically important risks and precautions identified in prescribing information. They are not simply a list of common side effects: warning sections focus on situations in which a potentially serious event, underlying medical condition, interacting treatment or unusually high drug exposure changes the safety context.
For current U.S. erectile-dysfunction tablet labeling, major warning topics include cardiovascular status, prolonged erection and priapism, sudden vision loss associated with non-arteritic anterior ischemic optic neuropathy (NAION), sudden hearing decrease or loss, hypotension with alpha-blockers or antihypertensive medicines, increased exposure with ritonavir, combination with other PDE5 inhibitors or ED therapies, and bleeding-related considerations.
This page uses the ED-tablet label as its main warning framework. Other sildenafil products can have indication- and formulation-specific prescribing information, so product context still matters. Common adverse reactions are covered on sildenafil side effects, while situations in which sildenafil should not be used are covered on sildenafil contraindications.
The Warnings and Precautions section of a prescribing label identifies risks that require particular attention when sildenafil is considered or used. Some warnings concern rare but potentially serious events, while others describe circumstances in which sildenafil's vasodilatory or pharmacokinetic properties may become more clinically important.
A warning does not necessarily mean that the event is common or that sildenafil has been proven to cause every reported event. For some postmarketing findings, the label explicitly notes uncertainty about causality. The purpose of the warning is to communicate the observed safety signal, the relevant uncertainty and the action described in prescribing information.
Warnings should also be kept separate from contraindications. A contraindication identifies a situation in which the label says the medicine should not be used, whereas a warning or precaution may call for assessment, caution, monitoring or prompt action if a particular event occurs.
| Safety Term | What It Means |
|---|---|
| Warning | Important potential risk requiring specific attention |
| Precaution | Clinical circumstance requiring additional care or assessment |
| Adverse reaction | Unwanted event reported during or after medicine use |
| Contraindication | Situation in which the product label states the medicine should not be used |
| Drug interaction | Effect of another medicine or substance on safety, exposure or pharmacological response |
Common side effects and major warnings answer different safety questions. The adverse-reaction section describes events observed during clinical trials or postmarketing experience, including relatively common reactions such as headache, flushing, dyspepsia, nasal congestion, abnormal vision and dizziness.
Warnings focus instead on situations with greater potential clinical consequence or a need for a particular response. Examples include an erection lasting more than four hours, sudden loss of vision, sudden hearing decrease or symptomatic hypotension in an interaction context.
An event can appear in more than one part of prescribing information because the same clinical problem may be both an adverse event and the subject of a specific warning. For the broader adverse-reaction profile rather than the warning framework, see sildenafil side effects.
| Category | Primary Question |
|---|---|
| Warnings | Which risks require special precaution or action? |
| Side effects | Which adverse reactions have been reported? |
| Contraindications | When does the label say sildenafil should not be used? |
| Interactions | Which other substances can change sildenafil exposure or effects? |
Sildenafil's cardiovascular warning has two related components: the cardiac demands of sexual activity and the drug's own systemic vasodilatory effect. Current U.S. labeling states that erectile-dysfunction treatments, including sildenafil, generally should not be used when sexual activity is inadvisable because of the person's underlying cardiovascular status.
Sildenafil can also produce a transient reduction in blood pressure. In healthy volunteers, the current label reports a mean maximum supine blood-pressure decrease of approximately 8.4 mmHg systolic and 5.5 mmHg diastolic. This effect is usually modest, but it becomes more relevant in people who may be particularly sensitive to vasodilators or who are using other blood-pressure-lowering treatments.
The label also notes a lack of controlled safety or efficacy data for certain higher-risk cardiovascular groups, including people with myocardial infarction, stroke or life-threatening arrhythmia within the previous six months; resting blood pressure below 90/50 mmHg or above 170/110 mmHg; and cardiac failure or coronary artery disease causing unstable angina.
| Cardiovascular Topic | Label Context |
|---|---|
| Sexual activity inadvisable because of cardiovascular status | ED treatment with sildenafil should generally not be used in this context |
| Systemic vasodilation | Can produce transient blood-pressure reduction |
| Recent MI, stroke or life-threatening arrhythmia | No controlled safety or efficacy data in the label for the preceding 6 months |
| Resting hypotension | Label identifies BP below 90/50 mmHg as a caution context |
| Marked resting hypertension | Label identifies BP above 170/110 mmHg as a caution context |
| Unstable angina / certain cardiac failure contexts | Limited controlled data; label advises caution |
Sildenafil and alpha-adrenergic blockers both have vasodilatory effects. When the two are used together, their blood-pressure-lowering effects can be additive, and in some patients this can produce symptomatic hypotension with symptoms such as dizziness, lightheadedness or fainting.
The label emphasizes that hemodynamic stability on alpha-blocker therapy matters when a PDE5 inhibitor is considered. Other variables, including volume depletion and additional antihypertensive medicines, can further change the blood-pressure response.
Sildenafil can also add to the effect of other antihypertensive medicines. In one labeled interaction study involving amlodipine, concomitant sildenafil produced an additional mean supine blood-pressure reduction of approximately 8 mmHg systolic and 7 mmHg diastolic. Detailed interaction coverage belongs on sildenafil drug interactions.
| Blood-Pressure Factor | Safety Relevance |
|---|---|
| Alpha-blocker | Additive vasodilation can cause symptomatic hypotension |
| Other antihypertensive medicines | Sildenafil may further lower blood pressure |
| Volume depletion | Can influence susceptibility to hypotension |
| Amlodipine study | Additional mean reduction of about 8/7 mmHg systolic/diastolic |
Organic nitrates and nitric-oxide donors belong in the contraindication framework rather than being described only as a general sildenafil warning. Sildenafil enhances the nitric oxide-cGMP pathway and can potentiate the blood-pressure-lowering effect of nitrates, which is why current U.S. labeling contraindicates their concomitant use.
Guanylate cyclase stimulators such as riociguat are also contraindicated. Combining a PDE5 inhibitor with a guanylate cyclase stimulator can further amplify cGMP-related vasodilation and increase the risk of hypotension.
Keeping these topics separate improves regulatory accuracy: they are closely related to sildenafil's blood-pressure warnings, but their label category is stronger than a precaution. See sildenafil and nitrates, sildenafil and riociguat and sildenafil contraindications for the dedicated treatment.
| Combination | Label Category | Primary Concern |
|---|---|---|
| Organic nitrates / nitric oxide donors | Contraindicated | Potentiation of hypotensive effects |
| Riociguat and other GC stimulators | Contraindicated | Additive cGMP-mediated blood-pressure lowering |
| Alpha-blockers | Warning / precaution context | Potential symptomatic hypotension |
Current sildenafil labeling reports infrequent postmarketing cases of prolonged erection lasting more than four hours and priapism, defined in the label as a painful erection lasting more than six hours. An erection that persists for more than four hours requires immediate medical assistance rather than waiting for it to resolve on its own.
The warning is important because untreated priapism can damage penile tissue and lead to permanent loss of erectile function. This is why the four-hour threshold is presented as an urgent action point even though the label distinguishes prolonged erection from the longer duration used in its description of priapism.
Additional caution is described for people with anatomical penile abnormalities such as angulation, cavernosal fibrosis or Peyronie's disease and for conditions that can predispose to priapism, including sickle cell anemia, multiple myeloma and leukemia.
| Priapism Topic | Label Information |
|---|---|
| Erection lasting more than 4 hours | Seek immediate medical assistance |
| Priapism | Label describes painful erections lasting more than 6 hours |
| Potential consequence if untreated | Penile tissue damage and permanent loss of potency |
| Anatomical risk context | Includes angulation, cavernosal fibrosis and Peyronie's disease |
| Predisposing hematologic conditions | Includes sickle cell anemia, multiple myeloma and leukemia |
The sildenafil label instructs patients to stop PDE5-inhibitor use and seek medical attention if sudden loss of vision occurs in one or both eyes. Sudden vision loss can be a sign of non-arteritic anterior ischemic optic neuropathy, or NAION, a rare optic-nerve condition that can cause decreased vision including permanent vision loss.
NAION has been reported rarely after marketing in temporal association with PDE5-inhibitor use. Observational studies cited in current labeling found an association between recent PDE5-inhibitor exposure and NAION, but the label explicitly states that these findings and postmarketing reports do not establish a causal relationship.
People who have previously experienced NAION are already at increased risk of recurrence, and the label advises caution in that group. A so-called crowded optic disc is also recognized as a risk factor, although the evidence is insufficient to support routine screening of prospective PDE5-inhibitor users for this uncommon anatomical characteristic.
| Vision Topic | Safety Meaning |
|---|---|
| Sudden loss of vision | Stop PDE5-inhibitor use and seek medical attention |
| NAION | Rare optic-nerve condition associated with sudden visual loss |
| Causal relationship with sildenafil | Not established by postmarketing reports or observational studies |
| Previous NAION | Higher recurrence risk; label advises caution |
| Crowded optic disc | Recognized risk factor, but routine screening is not supported by sufficient evidence |
Current prescribing information advises patients to stop taking PDE5 inhibitors, including sildenafil, and seek prompt medical attention if sudden decrease or loss of hearing occurs. Reported episodes have sometimes also involved tinnitus or dizziness.
These hearing events were reported in temporal association with PDE5-inhibitor use, including sildenafil. The label does not state that sildenafil has been proven to cause every reported case; it specifically notes that the available information cannot determine whether the events were directly caused by PDE5 inhibition, underlying risk factors or other causes.
This is another example of why a warning should not be reduced to an adverse-event frequency statement. The clinically important feature is the sudden nature of the hearing change and the label-directed need for prompt assessment.
| Hearing Topic | Label Context |
|---|---|
| Sudden hearing decrease | Stop PDE5 inhibitor and seek prompt medical attention |
| Sudden hearing loss | Prompt medical assessment advised |
| Associated symptoms | May include tinnitus or dizziness |
| Direct causality established? | No; the label states that causality cannot be determined from available reports |
Warnings are also relevant when another medicine substantially raises sildenafil exposure. Ritonavir is a prominent label example: concomitant administration produced an approximately 11-fold increase in sildenafil AUC, demonstrating how strongly metabolic inhibition can alter systemic exposure.
The label notes that decreased blood pressure, syncope and prolonged erection were observed in some healthy volunteers exposed to very high sildenafil levels. This does not mean that every CYP interaction produces the same magnitude of change, but it illustrates why exposure-modifying medicines can change the safety profile.
The metabolic basis belongs primarily on the interaction and CYP pages rather than being duplicated here. See sildenafil and CYP3A4 and sildenafil drug interactions for deeper coverage.
| Exposure Factor | Warning Context |
|---|---|
| Ritonavir | Substantially increases sildenafil systemic exposure |
| Reported AUC change | Approximately 11-fold increase in the label interaction study |
| Potential high-exposure events | Decreased blood pressure, syncope and prolonged erection |
| Other CYP modifiers | Require medicine-specific interaction assessment |
The safety and efficacy of combining sildenafil ED tablets with other PDE5 inhibitors or other erectile-dysfunction treatments have not been established in current labeling. This includes other sildenafil-containing products, such as sildenafil used in the Revatio pulmonary-arterial-hypertension context.
Because PDE5 inhibitors have vasodilatory effects, combining treatments can potentially produce additional blood-pressure lowering. Current labeling therefore states that such combinations are not recommended.
This warning is particularly important for avoiding the assumption that separate brand names necessarily represent unrelated active exposure. Sildenafil can appear in more than one product context, as explained on sildenafil uses and sildenafil and Revatio.
| Combination Topic | Label Position |
|---|---|
| Other PDE5 inhibitors | Safety and efficacy of combination not established |
| Other sildenafil-containing PAH products | Combination not recommended |
| Other ED therapies | Combination safety and efficacy not established |
| Potential concern | Additional blood-pressure lowering |
Bleeding appears in the Warnings and Precautions section, but the evidence requires careful wording. Postmarketing bleeding events have been reported in people taking sildenafil, yet the current label states that a causal relationship has not been established.
In human studies, sildenafil alone or with aspirin did not alter bleeding time. Laboratory data show effects on platelet-related signaling under some experimental conditions, and animal data have shown an additive bleeding-time effect with heparin, but that specific interaction has not been studied in humans.
The label therefore emphasizes uncertainty rather than claiming that sildenafil is a general anticoagulant. It states that safety is unknown in people with bleeding disorders and in those with active peptic ulceration.
| Bleeding Topic | Evidence Context |
|---|---|
| Postmarketing bleeding reports | Reported, but causal relationship not established |
| Sildenafil alone in human studies | No effect on bleeding time described |
| Sildenafil with aspirin | No effect on bleeding time described in the cited human data |
| Bleeding disorders | Safety described as unknown |
| Active peptic ulceration | Safety described as unknown |
Current prescribing information also includes counseling about sexually transmitted diseases. Sildenafil treats erectile-dysfunction physiology; it does not provide protection against sexually transmitted infections, including HIV.
This point is not a pharmacological toxicity warning like hypotension or priapism. It appears in the warning-and-precaution framework because patients should not interpret improved erectile function as protection against infection transmission.
The distinction helps keep the page aligned with the actual prescribing-information structure rather than limiting warnings only to adverse drug reactions.
| Question | Answer |
|---|---|
| Does sildenafil prevent sexually transmitted infections? | No |
| Does sildenafil protect against HIV? | No |
| Why is this included in labeling? | Patient counseling and risk-prevention context |
The warning structure summarized above is based primarily on current U.S. labeling for sildenafil tablets used in the erectile-dysfunction context. Sildenafil is also marketed in other product and indication contexts, and those labels can contain additional or differently organized safety information.
For example, sildenafil products used for pulmonary arterial hypertension involve a different patient population, dosing framework and benefit-risk context. A warning from one product label should therefore not automatically be treated as the complete safety section for every sildenafil-containing product.
The broader indication map is available on sildenafil uses, while formulation and product distinctions are covered on sildenafil formulations and sildenafil brand names.
| Context | Why It Matters |
|---|---|
| ED sildenafil tablets | Primary warning framework summarized on this page |
| PAH sildenafil products | Different indication and patient context |
| Formulation | Can affect the applicable product labeling |
| Jurisdiction | Approved wording and product information can differ |
Renal and hepatic function can change sildenafil exposure, but these topics should not be expanded here into duplicate pharmacokinetic pages. Their importance to safety comes from the fact that altered clearance or metabolism can increase systemic exposure in some populations.
The detailed PK effects are handled separately so this page can remain focused on warnings and precautions rather than becoming a general special-populations monograph.
See sildenafil pharmacokinetics in renal impairment, sildenafil pharmacokinetics in hepatic impairment and sildenafil PK variability.
| Exposure Topic | Dedicated Resource |
|---|---|
| Renal impairment | Renal Impairment Pharmacokinetics |
| Hepatic impairment | Hepatic Impairment Pharmacokinetics |
| General PK variability | Sildenafil PK Variability |
Major warnings and precautions in current U.S. ED-tablet labeling include cardiovascular considerations, prolonged erection and priapism, sudden vision loss associated with NAION, sudden hearing decrease or loss, hypotension with alpha-blockers or antihypertensive medicines, increased exposure with ritonavir, combination with other PDE5 inhibitors or ED treatments, and bleeding-related considerations.
No. Side effects describe reported adverse reactions, while warnings and precautions highlight clinically important risks, circumstances requiring caution or events for which the label describes a particular response.
Current prescribing information states that an erection persisting longer than four hours requires immediate medical assistance because untreated prolonged erection or priapism can damage penile tissue.
The label advises stopping PDE5-inhibitor use and seeking medical attention for sudden loss of vision in one or both eyes because it may be a sign of NAION. Reports and observational associations have not established a direct causal relationship between sildenafil and every NAION event.
The label advises stopping PDE5 inhibitors and seeking prompt medical attention for sudden decrease or loss of hearing. Tinnitus or dizziness can accompany reported events, and direct causality has not been established.
Yes. Sildenafil has systemic vasodilatory effects and can transiently lower blood pressure. The effect is especially relevant with other vasodilators such as alpha-blockers, antihypertensive medicines, nitrates or guanylate cyclase stimulators.
No. Organic nitrates and nitric-oxide donors are contraindicated with sildenafil in current U.S. labeling because sildenafil can potentiate their hypotensive effects.
Yes. Current labeling contraindicates concomitant use with guanylate cyclase stimulators such as riociguat because the combination can increase hypotensive effects.
Ritonavir can markedly increase sildenafil exposure. Current labeling reports an approximately 11-fold increase in sildenafil AUC with concomitant ritonavir, which can increase the risk of exposure-related adverse reactions.
Current U.S. labeling states that the safety and efficacy of combining sildenafil with other PDE5 inhibitors, other sildenafil-containing PAH treatments or other erectile-dysfunction therapies have not been established and that such combinations are not recommended.
Postmarketing bleeding events have been reported, but current labeling states that a causal relationship has not been established. Safety is described as unknown in patients with bleeding disorders or active peptic ulceration.
Not necessarily. This page primarily summarizes current U.S. erectile-dysfunction tablet labeling. Other sildenafil products, formulations, indications and jurisdictions can have different or additional prescribing information.